Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor
Open Access
- 1 November 2001
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 15 (13) , 2489-2496
- https://doi.org/10.1096/fj.01-0671com
Abstract
Vasoactive intestinal peptide (VIP) and its G-protein-coupled receptors (VPAC1 and VPAC2 Rs) are prominent in the immune system. In T cells, VPAC1 R is expressed constitutively whereas VPAC2 R is induced only after stimulation of the T cell receptor (TCR) or exposure to some cytokines. VPAC1 R and VPAC2 R also transduce different effects of VIP on T cells. Constitutive expression of VPAC2 R selectively in CD4+ T cells (helper-inducer Th cells) of transgenic (TG) C57BL/6 mice directed by the lck tyrosine kinase promoter is now shown to evoke production of more Th2-type interleukins 4 and 5, and less Th1-type interferon y after TCR activation. VPAC2 R TG mice consequently have significant elevations of blood IgE, IgG1, and eosinophils. VPAC2 R TG mice also show increased IgE antibody responses, which mediate heightened cutaneous allergic reactions, and have depressed delayed-type hypersensitivity. VIP enhancement of the ratio of Th2 cell to Th1 cell cytokines thus evokes an allergic state in normally nonallergic mice, which suggests the possibility of neuropeptide contributions to immune phenotypic alterations in human hypersensitivity diseases.—Voice, J. K., Dorsam, G., Lee, H., Kong, Y., Goetzl, E. J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15, 2489–2496 (2001)Keywords
Funding Information
- National Institutes of Health (AI 29912)
This publication has 22 references indexed in Scilit:
- Development of High Affinity Selective VIP1 Receptor AgonistsPeptides, 1997
- Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-α production by whole blood cells from healthy young and old subjectsJournal of Neuroimmunology, 1996
- Chromosomal Localization in Mouse and Human of the Vasoactive Intestinal Peptide Receptor Type 2 Gene: A Possible Contributor to the Holoprosencephaly 3 PhenotypeGenomics, 1996
- Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytesJournal of Neuroimmunology, 1996
- Human Vasoactive Intestinal Peptide1 Receptors Expressed by Stable Transfectants Couple to 2 Distinct Signaling PathwaysBiochemical and Biophysical Research Communications, 1994
- Specific Recognition of the Human Neuroendocrine Receptor for Vasoactive Intestinal Peptide by Anti-Peptide AntibodiesMolecular and Cellular Neuroscience, 1994
- Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptideJournal of Allergy and Clinical Immunology, 1993
- Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complexJournal of Neuroimmunology, 1993
- Delayed thymocyte development induced by augmented expression of p56lck.The Journal of Experimental Medicine, 1991
- Vasoactive Intestinal Polypeptide and Related Peptides. Isolation and ChemistryaAnnals of the New York Academy of Sciences, 1988